Cui 2015.

Methods	Study design: randomised clinical trial Study duration: September 2012 to October 2014 Duration of follow‐up: 3 years Setting: hospital
Participants	Inclusion criteria: diagnosed as HCC; tumour diameter of 2‐10 cm and tumour number ≤ 3; liver function of Child‐Pugh Class A or B; willing to sign a written informed consent document Age (mean ± SD, range): TACE + RFA: 45.38 ± 4.72 years, 21‐70 years; TACE alone: 45. 96 ± 5.12 years, 22‐70 years Male (n/total): TACE + RFA: 65/110; TACE alone: 66/110 With single tumour/multiple tumours (patients): TACE + RFA: 79/31; TACE alone: 75/35 Child‐Pugh Class (patients): Class A: TACE + RFA: 77; TACE alone: 66 Class B: TACE + RFA: 33; TACE alone: 44
Interventions	TACE + RFA group (n = 110): TACE: Chemotherapeutic drugs: epirubicin 40 mg; oxaliplatin 100 mg. For patients with poor liver function, the dose of chemotherapeutic drugs was reduced. RFA: The interval between TACE and RFA was 2 weeks. COSMAN MEDICAL, INC, RFG‐4 system. Ablation margin of 1 cm. Ultrasound‐guided RFA TACE group (n = 110): Chemotherapeutic drugs: epirubicin 40 mg; oxaliplatin 100 mg. For patients with poor liver function, the dose of chemotherapeutic drugs was reduced.
Outcomes	Clinical efficacy: measured by contrast‐enhanced CT 1‐, 2‐, and 3‐year survival rates Adverse events
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.